Strategic Collaborations Starpharma frequently engages in partnerships and research agreements with major pharma players such as MSD (Merck) for DEP ADC research, indicating a strong openness to collaboration and potential co-development or licensing deals for its DEP delivering platform and dendrimer technology.

Pipeline Leverage With programs spanning DEP drug delivery, VivaGel, and DEP cabazitaxel in phase 2, Starpharma holds a diverse pipeline that could attract corporate partners seeking oncology, antiviral, or locally delivered therapeutics, presenting multiple entry points for co-development or acquisition discussions.

Regulatory Prospects Recent patent activity around DEP cabazitaxel strengthens IP protection and asset value, suggesting opportunities for licensing negotiations or strategic investments to accelerate regulatory approvals and market access in oncology indications.

Infectious Disease Focus Starpharma has shown continued emphasis on antiviral programs including nasal spray candidates and COVID-19 related approaches, creating potential sales conversations with pharma companies seeking preventative or early-treatment solutions for respiratory viruses and RSV.

Regional Footprint Headquartered in Australia with a global leadership position in dendrimer-based therapeutics and a mid-sized workforce, Starpharma may be receptive to regional partnerships or distributor arrangements to expand into key markets while leveraging its DEP technology platform.